Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
36
HQL Quote, Financials, Valuation and Earnings
Last price:
$13.47
Seasonality move
:
4.03%
Day range:
$13.16 - $13.54
52-week range:
$12.76 - $15.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
94.5K
Avg. volume:
99.2K
1-year change:
4.01%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
$13.50 | -- | -- | -- | $0.50 | 0% | -- |
|
BBH
VanEck Biotech ETF
|
$158.56 | -- | -- | -- | $0.71 | 0% | -- |
|
HQH
abrdn Healthcare Investors
|
$16.29 | -- | -- | -- | $0.62 | 0% | -- |
|
IBB
iShares Biotechnology ETF
|
$132.73 | -- | -- | -- | $0.06 | 0.29% | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
$21.60 | -- | -- | -- | $0.09 | 1.09% | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
$22.64 | -- | -- | -- | $0.11 | 0.98% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | 1.173 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 1.127 | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | 1.083 | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | 1.446 | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | 1.252 | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | 1.497 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- | -- |
|
IBB
iShares Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IBBQ
Invesco Nasdaq Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
IDNA
iShares Genomics Immunology and Healthcare ETF
|
-- | -- | -- | -- | -- | -- |
abrdn Life Sciences Investors vs. Competitors
-
Which has Higher Returns HQL or BBH?
VanEck Biotech ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About HQL or BBH?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than VanEck Biotech ETF, analysts believe abrdn Life Sciences Investors is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is HQL or BBH More Risky?
abrdn Life Sciences Investors has a beta of 0.748, which suggesting that the stock is 25.182% less volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.727, suggesting its less volatile than the S&P 500 by 27.303%.
-
Which is a Better Dividend Stock HQL or BBH?
abrdn Life Sciences Investors has a quarterly dividend of $0.50 per share corresponding to a yield of 0%. VanEck Biotech ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.71 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or BBH?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns HQL or HQH?
abrdn Healthcare Investors has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat abrdn Healthcare Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- HQHabrdn Healthcare Investors-- -- -- -
What do Analysts Say About HQL or HQH?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Healthcare Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than abrdn Healthcare Investors, analysts believe abrdn Life Sciences Investors is more attractive than abrdn Healthcare Investors.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 HQHabrdn Healthcare Investors0 0 0 -
Is HQL or HQH More Risky?
abrdn Life Sciences Investors has a beta of 0.748, which suggesting that the stock is 25.182% less volatile than S&P 500. In comparison abrdn Healthcare Investors has a beta of 0.769, suggesting its less volatile than the S&P 500 by 23.068%.
-
Which is a Better Dividend Stock HQL or HQH?
abrdn Life Sciences Investors has a quarterly dividend of $0.50 per share corresponding to a yield of 0%. abrdn Healthcare Investors offers a yield of 0% to investors and pays a quarterly dividend of $0.62 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. abrdn Healthcare Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or HQH?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than abrdn Healthcare Investors quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than abrdn Healthcare Investors's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while abrdn Healthcare Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for abrdn Healthcare Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- HQHabrdn Healthcare Investors-- -- -- --
-
Which has Higher Returns HQL or IBB?
iShares Biotechnology ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat iShares Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- IBBiShares Biotechnology ETF-- -- -- -
What do Analysts Say About HQL or IBB?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than iShares Biotechnology ETF, analysts believe abrdn Life Sciences Investors is more attractive than iShares Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 IBBiShares Biotechnology ETF0 0 0 -
Is HQL or IBB More Risky?
abrdn Life Sciences Investors has a beta of 0.748, which suggesting that the stock is 25.182% less volatile than S&P 500. In comparison iShares Biotechnology ETF has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.046%.
-
Which is a Better Dividend Stock HQL or IBB?
abrdn Life Sciences Investors has a quarterly dividend of $0.50 per share corresponding to a yield of 0%. iShares Biotechnology ETF offers a yield of 0.29% to investors and pays a quarterly dividend of $0.06 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. iShares Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or IBB?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than iShares Biotechnology ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than iShares Biotechnology ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while iShares Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for iShares Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- IBBiShares Biotechnology ETF-- -- -- --
-
Which has Higher Returns HQL or IBBQ?
Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- -
What do Analysts Say About HQL or IBBQ?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe abrdn Life Sciences Investors is more attractive than Invesco Nasdaq Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 IBBQInvesco Nasdaq Biotechnology ETF0 0 0 -
Is HQL or IBBQ More Risky?
abrdn Life Sciences Investors has a beta of 0.748, which suggesting that the stock is 25.182% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HQL or IBBQ?
abrdn Life Sciences Investors has a quarterly dividend of $0.50 per share corresponding to a yield of 0%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.09% to investors and pays a quarterly dividend of $0.09 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or IBBQ?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- IBBQInvesco Nasdaq Biotechnology ETF-- -- -- --
-
Which has Higher Returns HQL or IDNA?
iShares Genomics Immunology and Healthcare ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat iShares Genomics Immunology and Healthcare ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- -
What do Analysts Say About HQL or IDNA?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Genomics Immunology and Healthcare ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than iShares Genomics Immunology and Healthcare ETF, analysts believe abrdn Life Sciences Investors is more attractive than iShares Genomics Immunology and Healthcare ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 IDNAiShares Genomics Immunology and Healthcare ETF0 0 0 -
Is HQL or IDNA More Risky?
abrdn Life Sciences Investors has a beta of 0.748, which suggesting that the stock is 25.182% less volatile than S&P 500. In comparison iShares Genomics Immunology and Healthcare ETF has a beta of 0.981, suggesting its less volatile than the S&P 500 by 1.86%.
-
Which is a Better Dividend Stock HQL or IDNA?
abrdn Life Sciences Investors has a quarterly dividend of $0.50 per share corresponding to a yield of 0%. iShares Genomics Immunology and Healthcare ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.11 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. iShares Genomics Immunology and Healthcare ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or IDNA?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than iShares Genomics Immunology and Healthcare ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than iShares Genomics Immunology and Healthcare ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while iShares Genomics Immunology and Healthcare ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for iShares Genomics Immunology and Healthcare ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- IDNAiShares Genomics Immunology and Healthcare ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
